Johnson & Johnson to Review Interim Data from the Phase 1/2 RPGR Clinical Trial and Janssen's Retinal Portfolio Strategy (Pre-recorded) Transcript

Jul 17, 2020 / NTS GMT
James F. List - Janssen Global Services, LLC - Global Therapeutic Area Head of Cardiovascular & Metabolism(CVM)

Hi. I'm Jim List, Global Head of the Cardiovascular, Metabolism and Retinal team at Janssen. I have the privilege of sharing how we're improving the lives of millions of people impacted by eye diseases.

Today, I'll highlight new data from the Phase I/II clinical trial of the gene therapy we're developing with MeiraGTx to treat X-linked retinitis pigmentosa, a rare inherited retinal disease. I'll also touch on why we're focused in this space and our overall strategy.

But first, please take a moment to read our cautionary note on forward-looking statements contained in this webcast.

Janssen is the pharmaceutical arm of Johnson & Johnson, and we are proud to be part of the broadest and most diversified health care company. Johnson & Johnson has long-standing leadership in both consumer and surgical devices through J&J Vision. Janssen's entry into eye disease only extends our commitment to support patients living with diseases of the eye.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot